We are gratified to see the additional data of Zucchetto and colleagues that further support the association of a4 integrin (CD49d) and CD38 expression in B-CLL.
1-3 Our recently published study discovered the link between CD38 expression and CD49d on leukemic CLL B cells as a result of gene expression profiling.
2 Using a novel method of surface antigen expression profiling to define the immunophenotype of specific B-CLL subsets, Zucchetto et al.
3 also recently reported that overexpression of CD49d is frequently observed in association with the above average expression of CD38, CD29, and CD49e. The additional data included in the Letter to the Editor extend both those studies 2, 3 by showing that CD49d expression correlates with the clinically important parameters and outcomes including advanced Rai stage at the time of diagnosis, unfavorable IgV H mutational status, time to progression, and overall survival. Of note, we defined CD38 positivity according to the mean fluorescence intensity (MFI) ratio of CD38-staining in relation to control staining 2 whereas Zucchetto et al. þ using the methods of our study, that is, displaying CD38 staining at levels above control staining. Moreover, it would also be of interest to see if the association of CD38 and/or CD49d expression has an even greater positive correlation with the Rai stage at the time of blood sampling as compared to the Rai stage at the time of diagnosis.
When reviewing our data in the context of Zucchetto et al. report, 1 it could be suggested that CD38 and CD49d may act synergistically to confer aggressive disease behavior. It is known that integrins such as CD49d require Ca þ þ to function as adhesion molecules in their role promoting homing and migration of lymphocytes. It is also known that CD38 functions as an ectoenzyme, catalyzing the conversion of NAD þ to cADPR, a potent Ca þ þ mobilizer. 4 Therefore, it is plausible that their coexpression could facilitate the homing of CLL B cells to tissue sites with a more favorable environmental milieu that in turn promotes more rapid leukemic B-cell growth and longer survival, a notion congruent with the finding that the level of a4 integrin expression is associated with the presence of clinically detectable lymphadenopathy.
5 It would also be interesting to determine if the function of integrins expressed on CLL B cells is impaired in CD38
À but not in CD38 þ CLL B cells. Given the provocative association of these two antigens on CLL B cells now demonstrated by both groups, 1-3 and the demonstration that CD38 and CD49d are complementary adverse prognostic factors in B-CLL, 1 it is tempting to speculate that these molecules play an important role in more progressive clinical disease. In summary, these reports suggest simultaneous assessment of both antigens may refine the usefulness of CD38 as a useful prognostic tool in B-CLL. Reply to Pittner et al.
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Leukemia ( In their published study, Pittner et al., 1 by comparing the gene expression profiling (GEP) of B-cell chronic lymphocytic leukemia (B-CLL) cells either expressing or not expressing the negative prognosticator CD38, were able to find a striking correlation between the overexpression of CD38 and that of the integrin a-chain CD49d. Interestingly, the same conclusion was reached in a recent study of ours, in which the expression of surface antigens, instead of genes, was analyzed.
2 So the two studies corroborate each other. In addition, we provided evidences on the clinical value of CD49d expression in B-CLL 
